Sugi Predict

Sugi Predict / Compounds / SCHEMBL9997126

SCHEMBL9997126

SCHEMBL9997126

O=C(O)c1ccc(NS(=O)(=O)c2ccc(-c3ccc4c(c3)CCO4)s2)cc1O

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PFKFB3 Q16875 6/20 0.54
▸ PKLR P30613 1/20 0.44
▸ LMNA P02545 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ PKM P14618 2/20 0.42
▸ DRD2 P14416 1/20 0.41
▸ HTR2C P28335 1/20 0.41
▸ DRD3 P35462 1/20 0.41
▸ HTR6 P50406 1/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ FABP4 P15090 3/20 0.41
▸ MAPT P10636 1/20 0.41
▸ HPGD P15428 1/20 0.40
▸ PLA2G10 O15496 1/20 0.39
▸ MCL1 Q07820 1/20 0.39
▸ FABP3 P05413 1/20 0.39
▸ FABP5 Q01469 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15055690 0.90 PKLR (0.44) PFKFB3PKLRLMNAHTTSMN1; SMN2
SCHEMBL9997373 0.85 PFKFB3 (0.51) PFKFB3PKLRSMN1; SMN2PKMHSD17B10
SCHEMBL30268499 0.84 PFKFB3 (0.76) PFKFB3PKMHSD17B10FABP4MAPT
SCHEMBL9997131 0.84 PFKFB3 (0.76) PFKFB3PKMHSD17B10FABP4MAPT
SCHEMBL9997077 0.81 PTGES2 (0.58) PFKFB3PKLRPKMHSD17B10FABP4
SCHEMBL9996955 0.79 PFKFB3 (0.57) PFKFB3HSD17B10ALDH1A1HPGDMCL1
SCHEMBL9997181 0.78 PKM (0.44) PFKFB3PKLRPKMFABP4MAPT
SCHEMBL9997230 0.77 ACLY (0.45) PFKFB3PKLRPKMALDH1A1FABP4
SCHEMBL19281316 0.76 PFKFB3 (0.50) PFKFB3PKLRPKMHSD17B10FABP4
SCHEMBL15055585 0.75 PFKFB3 (0.62) PFKFB3PKLRLMNAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2794009-B1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2017-08-30 — — EP claimed
EP-2794009-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER Kancera AB (SE) 2014-10-29 — — EP claimed
WO-2013093095-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2013-06-27 — — WO claimed
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 — — WO claimed
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 — — US disclosed
CN-113396145-A PFKFB3 inhibitors and uses thereof 盖罗发现有限责任公司 2021-09-14 — — CN disclosed
WO-2020080979-A1 PFKFB3 INHIBITORS AND THEIR USES GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) 2020-04-23 — — WO disclosed
US-10000449-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer KANCERA AB (SE) 2018-06-19 — — US disclosed
EP-2794009-B1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2017-08-30 — — EP disclosed
US-9718809-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer KANCERA AB (SE) 2017-08-01 — — US disclosed
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2016-08-04 — — US disclosed
US-20150025068-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2015-01-22 — — US disclosed
CN-104168958-A Diaryl sulfonamides useful for the treatment of inflammation and cancer KANCERA AB 2014-11-26 — — CN disclosed
EP-2794009-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER Kancera AB (SE) 2014-10-29 — — EP disclosed
WO-2013093095-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2013-06-27 — — WO disclosed
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 — — WO disclosed
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025068-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER NFKBIA, IL6, LITAF PFKFB3 909/4885PKLR 502/4885LMNA 2116/4885
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER NFKBIA, IL6, LITAF PFKFB3 988/4885PKLR 499/4885LMNA 2112/4885
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES PFKFB3, PFKFB4, PFKFB1 PFKFB3 1/4885PKLR 43/4885LMNA 4383/4885
US-10000449-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer NFKBIA, IL6, LITAF PFKFB3 988/4885PKLR 499/4885LMNA 2112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.